Home Cart Sign in  
Chemical Structure| 2005486-31-5 Chemical Structure| 2005486-31-5

Structure of Ebopiprant
CAS No.: 2005486-31-5

Chemical Structure| 2005486-31-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

OBE022 is an oral and selective prostaglandin F2α (PGF2α) receptor antagonist, with Kis of 1 nM, 26 nM for human and rat FP receptors, respectively.

Synonyms: OBE022

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ebopiprant

CAS No. :2005486-31-5
Formula : C30H34FN3O5S2
M.W : 599.74
SMILES Code : N[C@@H](C(C)C)C(OCC[C@H](NC([C@@H]1SCCN1S(=O)(C2=CC=C(C3=CC=CC=C3)C=C2)=O)=O)C4=CC=C(F)C=C4)=O
Synonyms :
OBE022
MDL No. :N/A

Safety of Ebopiprant

Related Pathways of Ebopiprant

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03369262 Preterm Labor Phase 2 Recruiting September 2021 Finland ... More >> Helsinki Universisty Hospital Recruiting Helsinki, Finland Contact: Investigator, MD          Spain Hospital La Paz Not yet recruiting Madrid, Spain Contact: Investigator, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.34mL

1.67mL

0.83mL

16.67mL

3.33mL

1.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories